Welcome to our dedicated page for Avita Medical news (Ticker: RCEL), a resource for investors and traders seeking the latest updates and insights on Avita Medical stock.
News and updates on AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) focus on its role as a therapeutic acute wound care company centered on the RECELL System and related wound care technologies. Company news frequently highlights developments in thermal burn and trauma treatment, clinical evidence for its products, and regulatory milestones in key markets.
Investors following RCEL news can expect coverage of financial results, revenue updates, and capital structure actions such as credit agreements and equity placements, as disclosed in Form 8-K filings and press releases. AVITA Medical regularly reports quarterly and annual financial performance, adjustments to revenue outlook, and steps taken to align operating expenses with its growth priorities.
News flow also includes clinical and scientific updates. AVITA Medical has reported data presentations at medical conferences, including systematic reviews of peer-reviewed literature and real-world registry analyses supporting the RECELL System in acute wound treatment. These items describe outcomes such as reduced donor site burden, faster healing, shorter hospital stays, and favorable economic impact in burn care.
Regulatory and market access developments are another recurring theme. The company has announced CE Mark approval for RECELL GO under the EU Medical Device Regulation, regulatory clearances for RECELL in Europe, Australia, and Japan, and support from Australia’s Medical Services Advisory Committee for the use of autologous skin cell suspension prepared with RECELL in severe burns. Corporate governance updates, such as board appointments and executive transitions, are also disclosed through AVITA Medical’s news releases.
For readers tracking RCEL, this news stream provides insight into the company’s clinical progress, regulatory status, financial performance, and leadership changes, all of which shape its position in the acute wound care and medical device landscape.
AVITA Medical (NASDAQ: RCEL) said interim CEO Cary Vance and CFO David O’Toole will present at the TD Cowen 46th Annual Health Care Conference in Boston on Wednesday, March 4, 2026 at 8:10 a.m. PT / 11:10 a.m. ET.
A live and archived webcast will be available via the company’s Events & Presentations page at its investor website.
AVITA Medical (NASDAQ: RCEL) will host an investor webinar briefing on Feb 18, 2026 at 2:00 PM PST (Feb 19, 2026 at 9:00 AM AEDT).
Interim CEO Cary Vance and CFO David O’Toole will review fourth-quarter and full-year 2025 financial and business results, followed by a Q&A. A replay will be posted on the company investor site.
AVITA Medical (NASDAQ: RCEL) reported Q4 2025 revenue of $17.6M and full-year revenue of $71.6M (+11% YoY). Q4 net loss was $11.6M (loss of $0.38/share); FY net loss was $48.6M (loss of $1.74/share). Gross margin was 82.1% for the year and cash plus marketable securities ended Q4 at $18.2M. The company closed a five-year credit facility providing up to $60M (initial $50M funded). 2026 revenue guidance: $80–85M.
Management highlighted improved cash efficiency, stabilization of reimbursement after MAC actions, ongoing clinical study enrollment, and execution-focused priorities for 2026.
AVITA Medical (NASDAQ: RCEL) presented data from 19 scientific abstracts at the 2026 Boswick Burn & Wound Symposium, including the first surgeon-reported integrated use of RECELL, PermeaDerm, and Cohealyx in single care pathways.
Initial histological findings from PermeaDerm and Cohealyx trials showed early blood vessel growth and organized tissue formation without increased inflammation. RECELL evidence across comparative studies and registries indicated smaller donor sites, similar or faster healing, fewer complications, and substantial hospital-stay reductions (nearly 16 days shorter in one older-patient study; ~33% less time in hospital in another registry analysis).
AVITA Medical (NASDAQ: RCEL) reported preliminary results and a 2026 outlook ahead of its J.P. Morgan presentation on Jan 14, 2026 at 5:15 p.m. PT. Q4 2025 revenue ~ $17.6M vs $18.4M a year earlier; FY 2025 revenue ~ $71.6M, up ~11% from $64.3M in 2024. The company secured a new five-year credit facility with Perceptive Advisors for up to $60M (initial $50M funded, $10M accordion available).
AVITA provided 2026 revenue guidance of $80–$85M (≈12%–19% growth) and disclosed TTM revenue covenants of $68.5M for Q1-2026 and $73M for FY2026, implying a required $15.4M revenue in Q1 2026. Clinical updates: Cohealyx-I fully enrolled and PermeaDerm-I >75% enrolled; data expected later in 2026.
AVITA Medical (NASDAQ: RCEL) announced board changes on January 5, 2026: Joe Woody was appointed as a non-executive director and Lou Panaccio retired after serving as Chairman from July 2014 to August 2025. The company is led by Interim CEO Cary Vance.
Mr. Woody brings more than two decades of medical-technology leadership, including serving as CEO of Avanos Medical from 2017 to 2024, prior service as President and CEO of Acelity, and over a decade on the AdvaMed board.
AVITA Medical (NASDAQ: RCEL) announced that CEO Cary Vance will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 at 5:15 p.m. PT.
A live audio webcast will be available via the company's Investor Relations Events & Presentations page and a replay will be posted after the presentation.
AVITA Medical (NASDAQ: RCEL) will present at the Piper Sandler 37th Annual Healthcare Conference on Thursday, December 4, 2025 at 8:30 a.m. EST. Management will be available for one-on-one investor meetings at the conference for registered attendees.
A live audio webcast of the presentation will be accessible under the Events & Presentations section of AVITA Medical's investor website at https://ir.avitamedical.com/events-and-presentations, and a replay will be available after the event.
AVITA Medical (NASDAQ: RCEL) will host an investor webinar briefing on November 12, 2025 at 2:00 p.m. PT (November 13, 2025 at 9:00 a.m. AEDT).
Interim CEO Cary Vance and CFO David O’Toole will review financial and business results from the company’s recent Q3 2025 earnings webcast and hold a live Q&A. Shareholders and prospective investors may register to submit questions in advance. A replay will be available on AVITA Medical’s investor website after the presentation.
AVITA Medical (NASDAQ: RCEL) reported Q3 2025 results for the quarter ended September 30, 2025. Commercial revenue was $17.1M, down 13% year-over-year. Operating expenses fell 24% to $23.0M, and net loss improved to $13.2M, or $0.46 per share, from $16.2M a year earlier. Cash, cash equivalents, and marketable securities totaled $23.3M at quarter end after a $13.8M private placement.
Key developments: RECELL GO received CE Mark under the EU MDR enabling launches in Germany, Italy, and the U.K.; real-world data showed a 36% reduction in hospital length-of-stay and approximately $42,000 per-patient cost savings versus split-thickness grafts; full-year 2025 revenue guidance was lowered to $70–$74M. The company amended its credit agreement, adding $500,000 to loan principal and resetting a revenue covenant to $70M for Q4 2025.